Drug Search Results
More Filters [+]

ZP-120

Alternative Names: zp-120, zp120, zp 120
Latest Update: 2022-07-01
Latest Update Note: PubMed Publication

Product Description

a novel ligand of the nociceptin/orphanin FQ (N/OFQ) peptide receptor, NOP. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12237257/)

Mechanisms of Action: NOP Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Zealand Pharma
Company Location: COPENHAGEN G7 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ZP-120

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Heart Failure, Acute|Heart Failure, Chronic|Heart Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-004801-11

P2

Active, not recruiting

Heart Failure, Chronic|Heart Failure, Acute

2005-06-18

NCT00283361

P2

Terminated

Heart Failure

None

Recent News Events